Xenon Pharmaceuticals Inc. financial data

Symbol
XENE on Nasdaq
Industry
Pharmaceutical Preparations
Location
200 3650 Gilmore Way, Burnaby, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.3K % +4.69%
Debt-to-equity 4.65 % -5.68%
Return On Equity -28.5 % -13.3%
Return On Assets -27.3 % -13.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 76.5M shares +1.47%
Common Stock, Shares, Outstanding 76.4M shares +1.39%
Entity Public Float 2.95B USD +20.6%
Common Stock, Value, Issued 1.46B USD +1.43%
Weighted Average Number of Shares Outstanding, Basic 77.9M shares +16.5%
Weighted Average Number of Shares Outstanding, Diluted 77.9M shares +16.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 210M USD +25.6%
General and Administrative Expense 68.9M USD +48%
Operating Income (Loss) -279M USD -30.5%
Nonoperating Income (Expense) 40.9M USD +30.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -238M USD -30.5%
Income Tax Expense (Benefit) -4.09M USD -1300%
Net Income (Loss) Attributable to Parent -234M USD -28.5%
Earnings Per Share, Basic -3.01 USD/shares -10.3%
Earnings Per Share, Diluted -3.01 USD/shares -10.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 143M USD -3.99%
Marketable Securities, Current 484M USD -1.07%
Accounts Receivable, after Allowance for Credit Loss, Current 1.47M USD +68.1%
Assets, Current 635M USD -1.5%
Deferred Income Tax Assets, Net 9.67M USD +1105%
Property, Plant and Equipment, Net 10.3M USD +6.48%
Operating Lease, Right-of-Use Asset 7.94M USD -13.6%
Assets 798M USD -17.3%
Employee-related Liabilities, Current 9.93M USD +33.7%
Liabilities, Current 35.6M USD +30.5%
Operating Lease, Liability, Noncurrent 7.65M USD -20.4%
Liabilities 43.2M USD +17.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.61M USD -1994%
Retained Earnings (Accumulated Deficit) -899M USD -35.2%
Stockholders' Equity Attributable to Parent 755M USD -18.6%
Liabilities and Equity 798M USD -17.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.2M USD -25.5%
Net Cash Provided by (Used in) Investing Activities -46.2M USD -199%
Common Stock, Shares, Issued 76.4M shares +1.39%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -89.7M USD -831%
Deferred Tax Assets, Valuation Allowance 267M USD +24.4%
Deferred Tax Assets, Gross 279M USD +28%
Operating Lease, Liability 9.02M USD -17.3%
Payments to Acquire Property, Plant, and Equipment 188K USD -91.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -236M USD -31.4%
Lessee, Operating Lease, Liability, to be Paid 10.2M USD -18.9%
Operating Lease, Liability, Current 1.37M USD +5.39%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.76M USD -0.74%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.69M USD -0.47%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Deferred Income Tax Expense (Benefit) 403K USD +39.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.15M USD -29.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.74M USD -5.34%
Deferred Tax Assets, Operating Loss Carryforwards 173M USD +44.7%
Unrecognized Tax Benefits 10.9M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.04M USD -43.2%
Operating Lease, Payments 411K USD +1.23%
Deferred Tax Assets, Net of Valuation Allowance 9.67M USD +1105%